Table 3

Pretreatment patient and disease characteristics
Characteristic All Glutamine (+) Glutamine (−) P-value
(N=104) (N=56) (N=48)
Age (years)
Median (Range) 57.6 (33–69) 58.7 (41–69) 56.5 (33–69) 0.41
Gender (N; %)
Male 67 (64.4) 35 (62.5) 32 (66.7) 0.62
Female 37 (35.6) 21(37.5) 16 (33.3)
Histology (N; %)
Squamous cell 64 (61.5) 34 (60.7) 30 (62.5) 0.81
Adeno 40 (38.5) 22 (39.3) 18 (37.5)
KPS (N; %)
90 – 100 58 (55.8) 30 (53.6) 28 (58.3) 0.76
70 - 80 46 (44.2) 26 (46.4) 20 (41.7)
TN-stage (N; %)
T1N3 7 (6,7) 4 (7,1) 3 (6,3) 0.38
T2N3 13 (12.5) 6 (10.7) 7 (14.5)
T3N3 17 (16.3) 10 (17.8) 7 (14.5)
T4N0 11 (10.6) 6 (10.7) 5 (10.4)
T4N1 16 (15.4) 8 (14.3) 8 (16.7)
T4N2 18 (17.3) 10 (17.9) 8 (16.7)
T4N3 22 (21.2) 12 (21.5) 10 (20.9)
T-stage (N; %)
1 7 (6.7) 4 (7.1) 3 (6.3) 0.33
2 13 (12.5) 6 (10.7) 7 (14.5)
3 17 (16.3) 10 (17.8) 7 (14.5)
4 67 (64.5) 36 (64.4) 31 (64. 7)
N-stage (N; %)
0 11 (10.6) 6 (10.7) 5 (10.4) 0.58
1 16 (15.4) 8 (14.3) 8 (16.7)
2 18 (17.3) 10 (17.9) 8 (16.7)
3 59 (56.7) 32 (57.1) 25 (58.1)
Bulk of T (N; %)
≤ 3.0 cm 8 (7.7) 3 (5.4) 5 (10.4) 0.42
3.01 - 5.0 cm 15 (14.4) 8 (14.3) 7 (14.6)
5.01 - 7.0 cm 43 (41.3) 24 (42.9) 19 (39.6)
> 7.0 cm 38 (36.6) 21 (37.4) 17 (35.4)
Bulk of largest N (N; %)
≤ 2.0 cm 58 (55.8) 30 (53.7) 28 (58.3) 0.22
> 2.0 cm 46 (44.2) 26 (46.3) 20 (41.7)
Chemotherapy
Platin – docetaxel 46 (44.2) 24 (42.9) 22 (45.8) 0.79
Platin - vinorelbine 58 (55.8) 32 (57.1) 26 (54.2)
Weight (kg)
Median (range) 66.3 (50.5-87.6) 65.9 (50.5-86.8) 67.2 (54.6-87.6) 0.37
BMI (kg/m2)
Median (range) 22.1 (18.4-27.8) 21.8 (18.4-27.6) 22.3 (18.8-27.8) 0.91

Abbreviations:BMI: Body mass index; KPS: Karnofsky performance score; N: Node; T: Tumor.

Topkan et al.

Topkan et al. BMC Cancer 2012 12:502   doi:10.1186/1471-2407-12-502

Open Data